The effect of betaine treatment on triglyceride levels and oxidative stress in the liver of ethanol-treated guinea pigs.
We investigated the effect of betaine supplementation on ethanol induced steatosis and alterations in prooxidant and antioxidant status in the liver of guinea pigs. Animals were fed with normal chow or betaine containing chow (2% w/w) for 30 days. Ethanol (3 g/kg, i.p.) was given for the last 10 days. We found that ethanol treatment caused significant increases in plasma transaminase activities, hepatic triglyceride and lipid peroxide levels. Significant decreases in glutathione (GSH), alpha-tocopherol and total ascorbic acid (AA) levels were also observed, but hepatic superoxide dismutase, glutathione peroxidase and glutathione transferase activities remained unchanged as compared with those in controls. Betaine treatment together with ethanol in guinea pigs is found to decrease hepatic triglyceride, lipid peroxide levels and serum transaminase activities and to increase GSH levels. No changes in alpha-tocopherol and total AA levels and antioxidant enzyme activities were observed with betaine treatment in alcohol treated guinea pigs. In addition, histopathological assessment of guinea pigs showed that betaine reduced the alcoholic fat accumulation in the liver. Based on these data, betaine treatment has a restoring effect on the alterations in triglyceride, lipid peroxide and GSH levels following ethanol ingestion.
Balkan
Jale
J
Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, Turkey.
Oztezcan
Serdar
S
Küçük
Mutlu
M
Cevikbaş
Uğur
U
Koçak-Toker
Necla
N
Uysal
Müjdat
M
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001622:Betaine / Q000494:pharmacology*; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D000431:Ethanol / Q000008:administration & dosage / Q000633:toxicity*; D005234:Fatty Liver / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D006168:Guinea Pigs; D007274:Injections, Intraperitoneal; D015227:Lipid Peroxidation / Q000187:drug effects; D008082:Lipotropic Agents / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D014280:Triglycerides / Q000378:metabolism*
D008082:Lipotropic Agents; D014280:Triglycerides; D000431:Ethanol; D001622:Betaine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase